IN2015DN03998A - - Google Patents

Info

Publication number: IN2015DN03998A
Authority: IN; India
Prior art keywords: medicaments; medicament; substituents; salt; compound
Prior art date: 2012-12-13

Application number

Other languages

English (en)

Inventor

Edgar Jacoby

Juergen Reinhardt

Niko Schmiedeberg

Carsten Spanka

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-13

Filing date

2013-12-12

Publication date

2015-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN03998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-12 Application filed by Novartis Ag filed Critical Novartis Ag

2015-10-02 Publication of IN2015DN03998A publication Critical patent/IN2015DN03998A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Inorganic Chemistry (AREA)
Plural Heterocyclic Compounds (AREA)

IN3998DEN2015 2012-12-13 2013-12-12 IN2015DN03998A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261736748P	2012-12-13	2012-12-13
PCT/IB2013/060859 WO2014091446A1 (en)	2012-12-13	2013-12-12	Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

Publications (1)

Publication Number	Publication Date
IN2015DN03998A true IN2015DN03998A (pt)	2015-10-02

Family

ID=50030361

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3998DEN2015 IN2015DN03998A (pt)	2012-12-13	2013-12-12

Country Status (24)

Country	Link
US (2)	US9649314B2 (pt)
EP (1)	EP2931282B1 (pt)
JP (1)	JP6076498B2 (pt)
KR (1)	KR101760586B1 (pt)
CN (2)	CN107569487A (pt)
AP (1)	AP2015008441A0 (pt)
AU (1)	AU2013358591B2 (pt)
BR (1)	BR112015013535A2 (pt)
CA (1)	CA2890692A1 (pt)
CL (1)	CL2015001610A1 (pt)
CR (1)	CR20150314A (pt)
CU (1)	CU20150061A7 (pt)
EA (1)	EA028673B1 (pt)
ES (1)	ES2709034T3 (pt)
HK (1)	HK1209637A1 (pt)
IL (1)	IL239244A0 (pt)
IN (1)	IN2015DN03998A (pt)
MA (1)	MA38157A1 (pt)
MX (1)	MX363437B (pt)
PE (1)	PE20151062A1 (pt)
PH (1)	PH12015501216A1 (pt)
SG (1)	SG11201503684WA (pt)
TN (1)	TN2015000262A1 (pt)
WO (1)	WO2014091446A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2890692A1 (en)	2012-12-13	2014-06-19	Novartis Ag	Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
US9896448B2 (en)	2014-06-03	2018-02-20	Novartis Ag	Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
PE20170086A1 (es) *	2014-06-03	2017-03-17	Novartis Ag	Derivados de naftiridinadiona
ES2743183T3 (es)	2014-06-03	2020-02-18	Novartis Ag	Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
CN109152747A (zh) *	2016-04-15	2019-01-04	Uab研究基金会	用于刺激提前终止密码子的通读的方法和化合物
EP3762383B1 (en) *	2018-03-06	2023-12-06	The United States of America, as represented by the Secretary, Department of Health and Human Services	Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (ja) *	2018-05-23	2019-11-28	京都薬品工業株式会社	リードスルー誘導剤およびその医薬用途
AU2021341508A1 (en)	2020-09-10	2023-05-25	Precirix N.V.	Antibody fragment against fap
JP2024504932A (ja)	2021-01-13	2024-02-02	モンテローザセラピューティクス，インコーポレイテッド	イソインドリノン化合物
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
WO2023213801A1 (en)	2022-05-02	2023-11-09	Precirix N.V.	Pre-targeting
WO2024194607A1 (en)	2023-03-17	2024-09-26	Tay Therapeutics Limited	Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2884170B2 (ja)	1989-08-24	1999-04-19	株式会社フジモト・ブラザーズ	５−デアザフラビン系化合物を有効成分とする制癌剤
US5908930A (en) *	1995-03-15	1999-06-01	Pfizer Inc.	5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6468990B1 (en)	1999-05-17	2002-10-22	Queen's University At Kingston	Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (en)	2002-07-15	2004-01-22	Combinatorx, Incorporated	Methods for the treatment of neoplasms
JP2007524596A (ja)	2003-02-28	2007-08-30	トランスフォーム・ファーマシューティカルズ・インコーポレイテッド	共結晶医薬組成物
UA84420C2 (ru)	2003-04-11	2008-10-27	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК
PT2390255T (pt)	2006-04-03	2016-10-24	Technion Res & Dev Foundation	Novos aminoglicosídeos e utilizações destes no tratamento de distúrbios genéticos
TW200819454A (en)	2006-08-23	2008-05-01	Neurogen Corp	Haloalkyl-substituted pyrimidinone derivatives
AU2008345225A1 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en)	2010-07-29	2012-02-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Flavin-nucleic acid ligand conjugates
ES2710854T3 (es)	2010-08-05	2019-04-29	Univ Lille	Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
CA2890692A1 (en)	2012-12-13	2014-06-19	Novartis Ag	Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

2013
- 2013-12-12 CA CA2890692A patent/CA2890692A1/en not_active Abandoned
- 2013-12-12 EP EP13826612.7A patent/EP2931282B1/en active Active
- 2013-12-12 AP AP2015008441A patent/AP2015008441A0/xx unknown
- 2013-12-12 US US14/652,102 patent/US9649314B2/en not_active Expired - Fee Related
- 2013-12-12 IN IN3998DEN2015 patent/IN2015DN03998A/en unknown
- 2013-12-12 KR KR1020157018231A patent/KR101760586B1/ko active IP Right Grant
- 2013-12-12 CN CN201710826258.0A patent/CN107569487A/zh active Pending
- 2013-12-12 CN CN201380064035.5A patent/CN104837490B/zh not_active Expired - Fee Related
- 2013-12-12 BR BR112015013535A patent/BR112015013535A2/pt not_active Application Discontinuation
- 2013-12-12 EA EA201591105A patent/EA028673B1/ru not_active IP Right Cessation
- 2013-12-12 SG SG11201503684WA patent/SG11201503684WA/en unknown
- 2013-12-12 MX MX2015007562A patent/MX363437B/es unknown
- 2013-12-12 WO PCT/IB2013/060859 patent/WO2014091446A1/en active Application Filing
- 2013-12-12 AU AU2013358591A patent/AU2013358591B2/en not_active Ceased
- 2013-12-12 PE PE2015000911A patent/PE20151062A1/es not_active Application Discontinuation
- 2013-12-12 JP JP2015547244A patent/JP6076498B2/ja not_active Expired - Fee Related
- 2013-12-12 ES ES13826612T patent/ES2709034T3/es active Active
2015
- 2015-05-29 PH PH12015501216A patent/PH12015501216A1/en unknown
- 2015-06-04 IL IL239244A patent/IL239244A0/en unknown
- 2015-06-05 MA MA38157A patent/MA38157A1/fr unknown
- 2015-06-09 TN TNP2015000262A patent/TN2015000262A1/fr unknown
- 2015-06-10 CL CL2015001610A patent/CL2015001610A1/es unknown
- 2015-06-12 CR CR20150314A patent/CR20150314A/es unknown
- 2015-06-12 CU CUP2015000061A patent/CU20150061A7/es unknown
- 2015-10-23 HK HK15110447.1A patent/HK1209637A1/xx unknown
2017
- 2017-04-04 US US15/478,778 patent/US20170266189A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104837490A (zh)	2015-08-12
US20150335646A1 (en)	2015-11-26
AU2013358591A1 (en)	2015-05-28
CL2015001610A1 (es)	2015-08-07
EA201591105A1 (ru)	2015-10-30
MA38157A1 (fr)	2016-12-30
CN107569487A (zh)	2018-01-12
MX363437B (es)	2019-03-22
AU2013358591B2 (en)	2016-08-25
IL239244A0 (en)	2015-07-30
SG11201503684WA (en)	2015-06-29
WO2014091446A1 (en)	2014-06-19
CU20150061A7 (es)	2015-12-23
EP2931282B1 (en)	2018-10-31
KR101760586B1 (ko)	2017-07-21
CA2890692A1 (en)	2014-06-19
JP2016503003A (ja)	2016-02-01
HK1209637A1 (en)	2016-04-08
PE20151062A1 (es)	2015-08-05
TN2015000262A1 (en)	2016-10-03
EA028673B1 (ru)	2017-12-29
CN104837490B (zh)	2017-10-03
EP2931282A1 (en)	2015-10-21
PH12015501216A1 (en)	2015-08-17
US9649314B2 (en)	2017-05-16
US20170266189A1 (en)	2017-09-21
CR20150314A (es)	2015-08-10
BR112015013535A2 (pt)	2017-07-11
MX2015007562A (es)	2015-10-14
JP6076498B2 (ja)	2017-02-08
KR20150092306A (ko)	2015-08-12
AP2015008441A0 (en)	2015-05-31
ES2709034T3 (es)	2019-04-12

Publication	Publication Date	Title
IN2015DN03998A (pt)	2015-10-02
NZ608116A (en)	2014-05-30	Triazine-oxadiazoles
UA116648C2 (uk)	2018-04-25	Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015008627A (es)	2015-09-23	Derivados de acido boronico y usos terapeuticos de los mismos.
IN2014DN10449A (pt)	2015-08-21
PH12015501083A1 (en)	2015-08-03	Novel pyridine derivatives
PH12013501600A1 (en)	2013-09-30	Novel heterocyclic derivatives
MD20140072A2 (ro)	2015-01-31	Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
PH12014501514A1 (en)	2014-10-08	New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015501843A1 (en)	2015-12-07	Novel pyrazol derivatives
IN2014DN01629A (pt)	2015-05-15
IN2015DN01119A (pt)	2015-06-26
MY174000A (en)	2020-03-03	Novel pyridine derivatives
PH12018501709A1 (en)	2019-08-14	Naphthridinedione derivatives
MX362879B (es)	2019-02-21	Usos novedosos.
MX2016004934A (es)	2016-12-20	Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
PH12015500585A1 (en)	2015-05-04	Modified hyaluronic acid derivatives and use thereof
IN2014DN10669A (pt)	2015-08-28
MX363458B (es)	2019-03-25	Nuevos derivados de tetrazolona.
MX365192B (es)	2019-05-23	Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
MX348841B (es)	2017-06-30	Derivados de pirimidooxazocina como inhibidores de mtor.
PH12015500373B1 (en)	2015-04-20	Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
TN2013000089A1 (en)	2014-06-25	Triazine-oxadiazoles
MA37778A1 (fr)	2016-05-31	Dérivés de carbamate/urée
TN2013000327A1 (en)	2015-01-20	Novel heterocyclic derivatives